Sanofi completes the acquisition of Vigil Neuroscience, Inc. Paris, August 6, 2025. Sanofi announces the completion of its acquisition of Vigil Neuroscience, Inc. (“Vigil”). This acquisition ...

Sanofi completes the acquisition of Vigil Neuroscience, Inc. Paris, August 6, 2025. Sanofi announces the completion of its acquisition of Vigil Neuroscience, Inc. (“Vigil”). This acquisition ...

Paris: Sanofi announces the completion of its acquisition of Vigil Neuroscience, Inc. This acquisition strengthens Sanofi's early-stage pipeline in neurology with VG-3927, a novel, ...

Sanofi finalise l’acquisition de Vigil Neuroscience, Inc. Paris, le 6 août 2025. Sanofi annonce la finalisation de l’acquisition de Vigil Neuroscience, Inc. (« Vigil »). Cette acquisition renforce le ...

Vigil Neuroscience , Inc. (NASDAQ:VIGL) announced Thursday that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act for its planned merger with Sanofi (NASDAQ:SNY) has ...

Sanofi rode the growing sales wave for blockbuster immunology drug Dupixent (dupilumab) in Q2 but reported ...

The announcement comes as Vigil’s stock trades near its 52-week high of $8.09, having surged over 318% in the past six months. The expiration of this waiting period satisfies one of the key conditions ...

Sanofi has finalized its takeover of Vigil Neuroscience for roughly $470 million, acquiring all outstanding shares at $8 each and issuing a $2-pe ...

Detailed price information for Vigil Neuroscience Inc (VIGL-Q) from The Globe and Mail including charting and trades.